Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BBI

Brickell Biotech (BBI) Stock Price, News & Analysis

Brickell Biotech logo

About Brickell Biotech Stock (NASDAQ:BBI)

Key Stats

Today's Range
N/A
50-Day Range
$0.77
$0.93
52-Week Range
N/A
Volume
31,300 shs
Average Volume
206,730 shs
Market Capitalization
$6.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Receive BBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brickell Biotech and its competitors with MarketBeat's FREE daily newsletter.

BBI Stock News Headlines

Brickell hotel sold by royal family member for $55M
I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Seattle Biotech News
Nuclear Receptor ROR-Gamma Market Size by 2030
Brickell City Centre
Biotech News
See More Headlines

BBI Stock Analysis - Frequently Asked Questions

Brickell Biotech, Inc. (NASDAQ:BBI) issued its quarterly earnings data on Thursday, August, 11th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($1.48) by $1.47. Brickell Biotech had a negative net margin of 643.48% and a negative trailing twelve-month return on equity of 156.10%.

Brickell Biotech shares reverse split before market open on Tuesday, July 5th 2022. The 1-45 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Brickell Biotech investors own include Tonix Pharmaceuticals (TNXP), TherapeuticsMD (TXMD), Alphabet (GOOG), NVIDIA (NVDA), Ocugen (OCGN), Meta Platforms (META) and Tesla (TSLA).

Company Calendar

Last Earnings
8/11/2022
Today
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BBI
Employees
16
Year Founded
2009

Profitability

Net Income
$-39,470,000.00
Net Margins
-643.48%
Pretax Margin
-643.48%

Debt

Sales & Book Value

Annual Sales
$4.64 million
Book Value
$9.75 per share

Miscellaneous

Free Float
2,744,000
Market Cap
$6.75 million
Optionable
Not Optionable
Beta
0.02

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:BBI) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners